ATE315031T1 - 2,4-disubstierte triazinderivate mit anti-hiv aktivität - Google Patents

2,4-disubstierte triazinderivate mit anti-hiv aktivität

Info

Publication number
ATE315031T1
ATE315031T1 AT99953980T AT99953980T ATE315031T1 AT E315031 T1 ATE315031 T1 AT E315031T1 AT 99953980 T AT99953980 T AT 99953980T AT 99953980 T AT99953980 T AT 99953980T AT E315031 T1 ATE315031 T1 AT E315031T1
Authority
AT
Austria
Prior art keywords
triazine derivatives
hiv activity
disubstituted triazine
disubstituted
hiv
Prior art date
Application number
AT99953980T
Other languages
English (en)
Inventor
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Paul Adriaan Jan Janssen
Robert W Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Aken Koen Jeanne Alfons Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE315031T1 publication Critical patent/ATE315031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99953980T 1998-11-10 1999-11-04 2,4-disubstierte triazinderivate mit anti-hiv aktivität ATE315031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24

Publications (1)

Publication Number Publication Date
ATE315031T1 true ATE315031T1 (de) 2006-02-15

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953980T ATE315031T1 (de) 1998-11-10 1999-11-04 2,4-disubstierte triazinderivate mit anti-hiv aktivität

Country Status (34)

Country Link
US (2) US6638932B1 (de)
EP (1) EP1129079B1 (de)
JP (1) JP2002529457A (de)
KR (1) KR100620402B1 (de)
CN (1) CN1207290C (de)
AP (1) AP1636A (de)
AR (1) AR021137A1 (de)
AT (1) ATE315031T1 (de)
AU (1) AU764472B2 (de)
BG (1) BG65160B1 (de)
BR (1) BR9915176A (de)
CA (1) CA2351203C (de)
CY (1) CY1105596T1 (de)
CZ (1) CZ20011532A3 (de)
DE (1) DE69929354T2 (de)
DK (1) DK1129079T3 (de)
EA (1) EA004501B1 (de)
EE (1) EE200100253A (de)
ES (1) ES2257081T3 (de)
HR (1) HRP20010310A2 (de)
HU (1) HUP0104395A3 (de)
ID (1) ID28545A (de)
IL (2) IL143024A0 (de)
MY (1) MY126781A (de)
NO (1) NO319788B1 (de)
NZ (1) NZ510919A (de)
OA (1) OA11675A (de)
PL (1) PL196523B1 (de)
PT (1) PT1129079E (de)
SI (1) SI1129079T1 (de)
SK (1) SK6022001A3 (de)
TR (1) TR200101319T2 (de)
TW (1) TW541305B (de)
WO (1) WO2000027828A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207290C (zh) * 1998-11-10 2005-06-22 詹森药业有限公司 2,4－二取代三嗪衍生物
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CN102503903A (zh) 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (de) * 1970-05-13 1974-07-18
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) * 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
NZ274978A (en) 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
ATE245641T1 (de) * 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
CN1207290C (zh) * 1998-11-10 2005-06-22 詹森药业有限公司 2,4－二取代三嗪衍生物

Also Published As

Publication number Publication date
CY1105596T1 (el) 2010-07-28
PL348145A1 (en) 2002-05-06
HRP20010310A2 (en) 2002-06-30
OA11675A (en) 2005-01-12
TR200101319T2 (tr) 2001-10-22
TW541305B (en) 2003-07-11
CA2351203A1 (en) 2000-05-18
DK1129079T3 (da) 2006-05-15
AR021137A1 (es) 2002-06-12
HUP0104395A2 (hu) 2002-04-29
HK1038232A1 (en) 2002-03-08
DE69929354D1 (de) 2006-03-30
EA004501B1 (ru) 2004-04-29
NO20011934L (no) 2001-04-19
ES2257081T3 (es) 2006-07-16
PL196523B1 (pl) 2008-01-31
WO2000027828A3 (en) 2000-09-21
DE69929354T2 (de) 2006-09-14
MY126781A (en) 2006-10-31
CN1207290C (zh) 2005-06-22
JP2002529457A (ja) 2002-09-10
EP1129079B1 (de) 2006-01-04
PT1129079E (pt) 2006-05-31
HUP0104395A3 (en) 2003-02-28
NO319788B1 (no) 2005-09-12
SK6022001A3 (en) 2002-01-07
IL143024A0 (en) 2002-04-21
WO2000027828A2 (en) 2000-05-18
US6638932B1 (en) 2003-10-28
KR100620402B1 (ko) 2006-09-13
IL143024A (en) 2006-06-11
BR9915176A (pt) 2001-08-14
AU1046200A (en) 2000-05-29
SI1129079T1 (sl) 2006-06-30
BG65160B1 (bg) 2007-04-30
NZ510919A (en) 2003-11-28
AP1636A (en) 2006-07-17
NO20011934D0 (no) 2001-04-19
BG105419A (en) 2001-11-30
US20050277641A1 (en) 2005-12-15
EP1129079A2 (de) 2001-09-05
US7015221B2 (en) 2006-03-21
ID28545A (id) 2001-05-31
CN1325387A (zh) 2001-12-05
EA200100534A1 (ru) 2001-10-22
CA2351203C (en) 2009-03-24
EE200100253A (et) 2002-12-16
CZ20011532A3 (cs) 2001-10-17
KR20010075234A (ko) 2001-08-09
AU764472B2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
DE69826127D1 (de) 2-substituierte 4,5-diarylimidazole
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
DE122005000003I1 (de) Heterocyclische Azahexanderivate mit Antiviraler wirkung.
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
ATE227282T1 (de) 2,4-diaminopyrimidin-derivate
DE69917327D1 (de) 3,3-biarylpiperidin- und 3,3-biarylmorpholinderivate
NO20003825D0 (no) 1,3,4 - oxadiazolonderivater
DK1149106T3 (da) 4,5-azolo-oxindoler
DE69714358D1 (de) 9,10-disubstituierte campothecinderivate mit antitumoraktivität
DK1129079T3 (da) 2,4-disubstituerede triazinderivater med anti-HIV aktivitet
EP1156040A4 (de) 2,4-dioxo-5-arylidenimido-1,3-pyrimidine
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
DE69815072D1 (de) Substituierte 2,4-diaminopyrimidine
DZ2644A1 (fr) Triazolo-Ä3,4-aÜ-pyridazine substituées en 1,2,4.
FI1336U1 (fi) Vaermevaexlare foer uppvaermning av uteluft med vatten, skaerkilt i s.k. vertikalvindkraftverk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129079

Country of ref document: EP

REN Ceased due to non-payment of the annual fee